Fromkin Andrew J. 4

What Happened

• Andrew J. Fromkin, a director of Immunovant, exercised options to acquire 196,601 common shares on May 28, 2026. The exercises reflected strikes of $4.99 (31,668 shares), $7.94 (71,492), $8.43 (77,181) and $14.70 (16,260) for a total exercise cost shown of $1,615,327.
• On the same day he sold a total of 221,951 shares in open-market transactions: 11,483 shares at a weighted-average price of $32.64 (total $374,805) and 210,468 shares at a weighted-average price of $33.56 (total $7,063,306). Combined sale proceeds reported ≈ $7.44 million.
• The filing also shows the derivative conversion lines at $0.00, which reflect the option exercises/conversions associated with these transactions.

Key Details

• Transaction date: May 28, 2026; Form 4 filed May 29, 2026 (appears timely).
• Options exercised: 196,601 shares total; aggregate reported exercise cost $1,615,327.
• Shares sold: 221,951 shares total; aggregate proceeds ≈ $7,438,111.
• Reported sale price ranges (per footnotes): $32.04–$33.035 for the smaller lot, and $33.04–$33.85 for the larger lot (weighted-average prices are reported on the Form 4).
• Footnote F3 indicates the stock options were fully vested.
• Shares owned after the transactions: Not specified in the supplied excerpt of the filing.

Context

• This is a common pattern called an exercise-and-sell (cashless) where an insider exercises vested options and sells some or all resulting shares; it can be routine for liquidity or tax/payment purposes and should not be interpreted as definitive market sentiment.
• The weighted-average prices and price ranges mean the shares were sold in multiple trades at slightly different prices; the filer offered to provide a breakdown on request per the footnotes.
• No 10b5-1 plan or other trading-plan language was indicated in the provided details.